全文获取类型
收费全文 | 20455篇 |
免费 | 1467篇 |
国内免费 | 94篇 |
专业分类
耳鼻咽喉 | 210篇 |
儿科学 | 580篇 |
妇产科学 | 504篇 |
基础医学 | 2867篇 |
口腔科学 | 612篇 |
临床医学 | 1854篇 |
内科学 | 4829篇 |
皮肤病学 | 445篇 |
神经病学 | 2003篇 |
特种医学 | 655篇 |
外科学 | 2174篇 |
综合类 | 138篇 |
现状与发展 | 1篇 |
一般理论 | 13篇 |
预防医学 | 1905篇 |
眼科学 | 308篇 |
药学 | 1318篇 |
中国医学 | 80篇 |
肿瘤学 | 1520篇 |
出版年
2024年 | 31篇 |
2023年 | 265篇 |
2022年 | 553篇 |
2021年 | 979篇 |
2020年 | 558篇 |
2019年 | 829篇 |
2018年 | 897篇 |
2017年 | 614篇 |
2016年 | 690篇 |
2015年 | 713篇 |
2014年 | 937篇 |
2013年 | 1083篇 |
2012年 | 1625篇 |
2011年 | 1685篇 |
2010年 | 898篇 |
2009年 | 769篇 |
2008年 | 1141篇 |
2007年 | 1195篇 |
2006年 | 1036篇 |
2005年 | 967篇 |
2004年 | 886篇 |
2003年 | 812篇 |
2002年 | 702篇 |
2001年 | 237篇 |
2000年 | 201篇 |
1999年 | 228篇 |
1998年 | 132篇 |
1997年 | 118篇 |
1996年 | 71篇 |
1995年 | 65篇 |
1994年 | 55篇 |
1993年 | 43篇 |
1992年 | 82篇 |
1991年 | 87篇 |
1990年 | 85篇 |
1989年 | 44篇 |
1988年 | 43篇 |
1987年 | 61篇 |
1986年 | 52篇 |
1985年 | 61篇 |
1984年 | 45篇 |
1983年 | 41篇 |
1981年 | 24篇 |
1980年 | 25篇 |
1979年 | 43篇 |
1978年 | 22篇 |
1975年 | 25篇 |
1974年 | 27篇 |
1973年 | 26篇 |
1969年 | 24篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
101.
de Almeida CE Pereira AJ Marechal MH Pereira G Cruz JC Ferraz JC Giordani AJ Khalil CM Martins RH Menegussi G Moreira D Rocha JR Pinto MA 《Physics in medicine and biology》1999,44(3):N31-N38
The lack of well established dosimetry protocols for HDR sources is a point of great concern regarding the uniformity of procedures within a particular country and worldwide. The main objective of this paper is to report the results from ten institutions of an intercomparison of calibration procedures for 192Ir HDR sources currently in use in Brazil. The treatment irradiator of one institution was calibrated by a reference system and used by all participants with their own measuring electrometers and ionization chambers under the same experimental conditions. Two methods were used: the calibration jig and the well-type ionization chamber. Each participant was allowed to use their own method and formalism. The results of this exercise were very positive since this was the first time in Brazil that a group of users gathered to share their experience and openly discuss the physical concepts behind the calibration procedures. The results were all within +/-3.0%, except one case where -4.6% was observed and later identified as a problem with the Nk value for x-rays. Though the magnitude of the deviations found was generally acceptable considering the diversity of formalisms currently in use, a proposal is now being prepared to be adopted as a national protocol. The identification of the institutions was left out for the sake of confidentiality. 相似文献
102.
p53 Accumulation Is a Prognostic Factor in Intestinal-Type Gastric Carcinoma but Not in the Diffuse Type 总被引:2,自引:0,他引:2
Roviello F Marrelli D Vindigni C De Stefano A Spina D Pinto E 《Annals of surgical oncology》1999,6(8):739-745
Background: The prognostic value of p53 nuclear accumulation in gastric cancer is still unclear, as shown by the discordant results still reported in the literature. In this study, we evaluated the correlation between p53 accumulation and long-term survival of patients resected for intestinal and diffuse-type gastric cancer.Methods: Eighty-three patients with carcinoma of the intestinal type and 53 patients with carcinoma of the diffuse type were included in the study. Immunohistochemical staining of the paraffin sections was performed by using monoclonal antibody DO1; cases were considered positive when nuclear immunostaining was observed in 10% or more of the tumor cells. Prognostic significance of different variables was investigated by univariate and multivariate analysis.Results: p53 positivity was found in 51.8% of intestinal-type and 50.9% of diffuse-type cases. No significant correlation between the rate of p53 overexpression and age, sex, tumor location, tumor size, depth of invasion, lymph node involvement, distant metastases, and surgical radicality was found in the two groups of patients. A statistically significant difference in survival rate was observed between p53-negative and p53-positive cases in the intestinal type (P < .05), confirmed by multivariate analysis (P < .005; relative risk = 3.09). On the contrary, no correlation with survival was found in diffuse-type cases according to p53 overexpression.Conclusions: These results suggest that the immunohistochemical detection of p53 accumulation is a useful indicator of poor prognosis in the intestinal but not in the diffuse type of gastric cancer, and are indicative of distinct molecular pathways and pattern of progression in the two histotypes. 相似文献
103.
104.
105.
Olson RE Sielecki TM Wityak J Pinto DJ Batt DG Frietze WE Liu J Tobin AE Orwat MJ Di Meo SV Houghton GC Lalka GK Mousa SA Racanelli AL Hausner EA Kapil RP Rabel SR Thoolen MJ Reilly TM Anderson PS Wexler RR 《Journal of medicinal chemistry》1999,42(7):1178-1192
Modification of the alpha-carbamate substituent of isoxazoline GPIIb/IIIa (alphaIIb beta3) antagonist DMP 754 (7) led to a series of alpha-sulfonamide and alpha-sulfamide diaminopropionate isoxazolinylacetamides which were found to be potent inhibitors of in vitro platelet aggregation. Aryl- and heteroaryl-alpha-sulfonamide groups, in conjunction with (5R)-isoxazoline (2S)-diaminopropionate stereochemistry, were found to impart a pronounced duration of antiplatelet effect in dogs, potentially due to high affinity for unactivated platelets. Isoxazolylsulfonamide 34b (DMP 802), a highly selective GPIIb/IIIa antagonist, demonstrated a prolonged duration of action after iv and po dosing and high affinity for resting and activated platelets. The prolonged antiplatelet profile of DMP 802 in dogs and the high affinity of DMP 802 for human platelets may be predictive of clinical utility as a once-daily antiplatelet agent. 相似文献
106.
Acute effects of the selective cholinergic channel activator (nicotinic agonist) ABT-418 in Alzheimer’s disease 总被引:4,自引:4,他引:0
To explore further the potential for cognitive enhancement utilizing nicotinic stimulation in Alzheimer’s disease (AD), six
otherwise healthy subjects with moderate AD received placebo and three doses (6, 12, and 23 mg) of the novel selective cholinergic
channel activator (ChCA) (nicotinic agonist) ABT-418 over 6 h in a double-blind, within-subjects, repeated-measures design.
Subjects showed significant improvements in total recall and a decline in recall failure on a verbal learning task. Qualitatively
similar improvements were seen in non-verbal learning tasks such as spatial learning and memory, and repeated acquisition.
No significant behavioral, vital sign, or physical side effects were seen. These results confirm that stimulating central
nicotinic receptors has acute cognitive benefit in AD patients. These findings suggest that selective ChCAs have a potential
therapeutic role in dementing disorders, and that further studies with this or similar agents in AD and/or Parkinson’s disease
are warranted.
Received: 27 February 1998/Final version: 9 September 1998 相似文献
107.
Jinee Rizzo Alexandra M. Levine Geoff R. Weiss Tillman Pearce Maura Kraynak Robert Mueck Susan Smith Daniel D. Von Hoff John G. Kuhn 《Investigational new drugs》1996,14(2):227-234
Summary Mitoguazone is a unique chemotherapeutic agent whose activity is believed to result primarily from the competitive inhibition of S-adenosyl-methionine decarboxylase leading to a disruption in polyamine biosynthesis. Initial clinical trials demonstrated that the dose-limiting toxicities (mucositis and myelosuppression) of Mitoguazone were both dose and schedule dependent. Early pharmacokinetic studies of Mitoguazone in man revealed a prolonged half-life. Concurrent with a recent Phase II trial of Mitoguazone in patients with AIDS related non-Hodgkin's lymphoma, the single dose pharmacokinetics of Mitoguazone were characterized. Twelve patients received 600 mg/m2 of intravenous Mitoguazone over 30 minutes on an intermittent every 2 week schedule. Blood, urine, cerebrospinal fluid (CSF), pleural fluid and tissue samples were collected and analyzed by HPLC. Mitoguazone was cleared from the plasma triexponentially with a harmonic mean terminal half-life of 175 hours and a mean residence time of 192 hours. Peak plasma levels occurred immediately post-infusion, ranged from 6.47 to 42.8 g/ml, and remained (for an extended period) well above the reported concentration for inhibition of polyamine biosynthesis. Plasma clearance averaged 4.73 l/hr/m2 with a relatively large apparent volume of distribution at steady-state of 1012 l/m2 indicating tissue sequestration. Renal excretion of unchanged Mitoguazone accounted for an average of 15.8% of the dose within 48 to 72 hours post-administration. Detectable levels of drug were present in random voided samples eight days post-dose. Mitoguazone levels in CSF ranged from 22 to 186 ng/ml post-dose with CSF/plasma ratios ranging from 0.6% to 7%. The pleural fluid/plasma ratio was approximately 1. Tissue levels of Mitoguazone were highest in the liver followed by lymph node, spleen and the brain. 相似文献
108.
Lexley M. Pinto Perdra Fitzroy A. Orrett Merle Balbirsingh 《Journal canadien d'anesthésie》1996,43(7):700-713
Purpose
This paper reviews the literature on the aetiology and therapy of bronchial hyperreactivity to describe the underlying pathophysiology, identify patients at risk and update knowledge on new and existing therapies.Source
Information was obtained from monograms on New Drugs for Asthma, Respiratory Medicine: recent advances, Agents and Actions Supplements, Pulmonary Pharmacology, Anesth Analg, the European Journal of Respiration and a Medline literature search.Principal findings
Reduced airway calibre, increased bronchial contractility, altered permeability of the bronchial mucosa, humoral and cellular mediators, and dysfunctional neural regulation are critical factors for bronchial hyperreactivity, a characteristic feature of hyperreactive airways which results in bronchoconstriction after exposure to varied stimuli. Preoperative anaesthetic considerations in these patients include FEV1 and PEFR testing to assess the severity and for optimal control of the condition. Bronchospasm causing hypoxaemia is the major intraoperative problem anticipated in these patients. Current therapeutic management of bronchoconstriction focusses on the β2 agonists, theophylline and steroids. Besides relaxing the airway smooth muscle these agents are all capable of altering bronchial inflammatory responses. Future developments of therapy are directed towards the inflammatory components of the disease.Conclusion
This review has presented background information on physiological mechanisms of smooth muscle contractility, pathophysiological alterations of bronchial contractility and the pharmacological basis of therapy in bronchoconstrictive disease. Information is presented to enable the prompt arrest and reversal of airway constriction, and to maintain prophylactic treatment during the perioperative period. Intraopera’tive bronchospasm is managed by adequate oxygenation and reversal of bronchoconstriction 相似文献109.
Although Hodgkin's disease (HD) is not usually associated
withcongenital or acquired immunodeficiency disorders, recent
evidencewould suggest a statistically significant increase in HD
amongindividuals infected with human immunodeficiency virus
(HIV).In the setting of underlying HIV infection, clinical and
pathologiccharacteristics of HD may differ from usual
expectations. Thus,70%-100% of HIV-infected
patients with HD present with systemic"B" symptoms.
Likewise, disseminated, stage III or IV diseaseis reported in
approximately 75%-90%. Bone marrow is a commonsite
of extranodal HD, occurring in 40%-50%. Complete
responserates after multiagent chemotherapy range from
approximately45% to 70%, although median survival
has been only in the rangeof approximately 18 months.
Hematologic toxicity from multiagentchemotherapy may be
substantial, even with the use of hematopoieticgrowth factor
support. It is apparent that new strategies oftherapeutic
intervention must be explored. 相似文献
110.
Souhami L Gil R Allan S Canary P Araujo C Pinto L 《International journal of oncology》1992,1(3):289-292
With the objective of testing the value of neoadjuvant chemotherapy in patients with stage III B carcinoma of the cervix, we began in 1984 a randomized, phase III trial comparing BOMP chemotherapy followed by pelvic radiotherapy versus pelvic radiotherapy alone. Patients were stratified by age, extension of parametrial involvement, and lymphangiographic findings. Despite a higher complete response rate, the overall 5-year survival was significantly inferior in the combined therapy group (39% vs 23%, P=0.02). Toxicity was more pronounced in the chemoradiation arm and 4 patients developed fatal pulmonary complications. Patterns of failure were similar in both groups. The use of primary chemotherapy in advanced carcinoma of the cervix was detrimental to the patients and its use outside a protocol setting is discouraged. 相似文献